Last edition
News about "neuroendocrine carcinoma "
Phanes PT217 Gets Orphan Drug Designation for Neuroendocrine Carcinoma
PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC.
Neuroendocrine Carcinoma | 17/08/2024 | By Aishwarya | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members